Darryl T. Martin

Dr. Darryl T. Martin

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
DMDarryl T. Martin
Darryl T. Martin
JSJill M. Steinbach
Jill M. Steinbach
JLJingchun Liu
Jingchun Liu
SSShogo Shimizu
Shogo Shimizu
HKHristos Z. Kaimakliotis
Hristos Z. Kaimakliotis
RWRobert M. Weiss
Robert M. Weiss
Penetration of the bladder permeability barrier (BPB) is a major challenge when treating bladder diseases via intravesical delivery. To increase transurothelial migration and tissue and tumor cell uptake, poly(lactic-co-glycolic acid; PLGA) nanoparticles (NP) were modified by addition of a low molecular weight (2.5 or 20 kDa) positively charged mucoadhesive polysaccharide, chitosan, to the NP surface. In designing these NPs, we balanced the adhesive properties of chitosan with the release and bioactivity of the siRNA. Chitosan-functionalized NPs demonstrated increased binding to and uptake in intravesically instilled mouse bladders and human ureter at 10 times the level of unmodified NPs. Furthermore, we extended the bioactivity of survivin siRNA in vitro for up to 9 days and demonstrated a decrease in proliferation when using chitosan-modified NPs relative to unmodified NPs. In addition, treatment of xenograft tumors with chitosan-modified NPs that encapsulate survivin siRNA (NP-siSUR-CH2.5) resulted in a 65% reduction in tumor volume and a 75% decrease in survivin expression relative to tumors treated with blank chitosan NPs (NP-Bk-CH2.5). Our low molecular weight chitosan delivery system has the capacity to transport large amounts of siRNA across the urothelium and/or to the tumor site, thus increasing therapeutic response. Mol Cancer Ther; 13(1); 71–81. ©2013 AACR.

1 May 2021 in Cellular Signalling
Verified
Journal Article
Closed access
SHShanshan He
Shanshan He
GLGang Li
Gang Li
ASAndreas G. Schätzlein
Andreas G. Schätzlein
PHPeter A. Humphrey
Peter A. Humphrey
RWRobert M. Weiss
Robert M. Weiss
DMDarryl T. Martin
Darryl T. Martin

1 November 2019 in Cellular Signalling
Verified
Journal Article
Closed access
XLXuanhao Li
Xuanhao Li
SHShanshan He
Shanshan He
YTYe Tian
Ye Tian
RWRobert M. Weiss
Robert M. Weiss
DMDarryl T. Martin
Darryl T. Martin

1 February 2019 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
DMDarryl T. Martin
Darryl T. Martin
HSHongliang Shen
Hongliang Shen
JSJill M. Steinbach-Rankins
Jill M. Steinbach-Rankins
XZXi Zhu
Xi Zhu
KJKatelyn K. Johnson
Katelyn K. Johnson
RWRobert M. Weiss
Robert M. Weiss
Predicting bladder cancer progression is important in selecting the optimal treatment for bladder cancer. Because current diagnostic factors regarding progression are lacking, new factors are needed to further stratify the curative potential of bladder cancer. Glycoprotein-130 (GP130), a transmembrane protein, is central to a number of signal transduction pathways involved in tumor aggressiveness, making it an attractive target. We hypothesize that if GP130 is found in an aggressive population of bladder tumors, then blocking GP130 expression may inhibit bladder cancer growth. Herein, we quantitatively show, using 11 patient samples and four bladder cancer cell lines, that GP130 is expressed in the aggressive human bladder tumors and in high-grade bladder cancer cell lines. Moreover, GP130 is significantly correlated with tumor grade, node category, tumor category, and patient outcome. We demonstrated a tumor-specific GP130 effect by blocking GP130 expression in bladder tumor cells, which resulted in decreased cell viability and reduced cell migration. Furthermore, we reduced tumor volume by approximately 70% compared with controls by downregulating GP130 expression using chitosan-functionalized nanoparticles encapsulating GP130 siRNA in an in vivo bladder cancer xenograft mouse model. Our results indicate that GP130 expression is linked to the aggressiveness of bladder tumors, and blocking GP130 has therapeutic potential in controlling tumor growth.

1 February 2022 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
DMDarryl T. Martin
Darryl T. Martin
JLJung Seok Lee
Jung Seok Lee
QLQiang Liu
Qiang Liu
GGGigi Galiana
Gigi Galiana
PSPreston C. Sprenkle
Preston C. Sprenkle
TFTarek M. Fahmy
Tarek M. Fahmy

1 April 2021 in Journal of Controlled Release
Verified
Journal Article
Closed access
GLGang Li
Gang Li
SHShanshan He
Shanshan He
ASAndreas G. Schätzlein
Andreas G. Schätzlein
RWRobert M. Weiss
Robert M. Weiss
DMDarryl T. Martin
Darryl T. Martin
IUIjeoma F. Uchegbu
Ijeoma F. Uchegbu